Lung Cancer clinical trial intelligence

A Randomized, Open-Label, Multicenter Phase III Study of SHR-A1811 for First-Line Treatment in Subjects With HER2-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

A Randomized, Open-Label, Multicenter Phase III Study of SHR-A1811 for First-Line Treatment in Subjects With HER2-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer is a PHASE3 clinical asset sponsored by Jiangsu HengRui Medicine Co., Ltd. in Non-Small Cell Lung Cancer With HER2- Mutations. SEO and diligence focus: SHR-A1811, PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Non-Small Cell Lung Cancer With HER2- Mutations

QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration

QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration is a PHASE1 clinical asset sponsored by Fuzhou General Hospital in NSCLC. SEO and diligence focus: QYJD Compound Preparation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: NSCLC

A Phase I Clinical Trial of PD-1 Knockout Engineered T Cells Treating Patients With Advanced Non-small Cell Lung Cancer

This Phase I clinical trial, sponsored by Sichuan University, investigates the safety and tolerability of PD-1 knockout engineered T cells in patients with advanced non-small cell lung cancer (NSCLC) who have progressed after standard treatments. The market for NSCLC therapies is significant, with increasing demand for innovative immunotherapies. The competitive landscape includes established immune checkpoint inhibitors like pembrolizumab and nivolumab. Successful outcomes could position this therapy as a novel treatment option, potentially leading to partnerships or licensing opportunities. Diligence should focus on regulatory pathways, manufacturing scalability, and the trial's safety profile to assess commercial viability.

Matched by conditions: Metastatic Non-small Cell Lung Cancer

Phase II Trial of Concurrent Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab (Avastin) in the Treatment of Patients With Limited Stage Small Cell Lung Cancer

This Phase II trial, sponsored by SCRI Development Innovations, LLC, evaluates a combination therapy of Irinotecan, Carboplatin, and Radiation Therapy followed by Bevacizumab in patients with limited stage small cell lung cancer (LS-SCLC). Given the high unmet need in LS-SCLC, successful outcomes could position this regimen favorably in a competitive landscape dominated by existing therapies. The trial's completion and subsequent results could provide critical data for potential partnerships or licensing opportunities, particularly with collaborators Genentech, Inc. and Pharmacia and Upjohn, who have vested interests in oncology therapeutics. The market for lung cancer treatments is substantial, with ongoing demand for improved efficacy and safety profiles, particularly in combination therapies.

Matched by conditions: Lung Cancer

A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers

The ongoing Phase II trial investigates the efficacy of Apatorsen (OGX-427), an antisense oligonucleotide targeting Hsp27, in combination with standard chemotherapy (gemcitabine/carboplatin) for patients with advanced squamous cell lung cancer (NSCLC). Given the limited treatment options for this patient population, successful outcomes could position Apatorsen as a novel therapeutic option, potentially enhancing the effectiveness of existing chemotherapy regimens. The market for lung cancer treatments is substantial, with increasing demand for innovative therapies. Competitive analysis indicates that while several therapies are available, few specifically target Hsp27, suggesting a unique market position if clinical efficacy is demonstrated. Diligence should focus on the trial's recruitment status, safety profile, and competitive landscape, particularly regarding other emerging therapies targeting similar pathways.

Phase I Clinical Study of Chimeric Antigen Receptor T Cells (C-13-60) in the Treatment of Carcinoembryonic Antigen (CEA) Positive Advanced Malignant Solid Tumors

Chongqing Precision Biotech Co., Ltd is advancing its C-13-60 CAR-T cell therapy targeting CEA-positive advanced malignant solid tumors through a Phase I clinical trial. The trial aims to establish safety, tolerability, and pharmacokinetics while preliminarily assessing efficacy. The targeted patient population includes those with advanced colorectal, esophageal, gastric, pancreatic, non-small cell lung, breast, and cholangiocarcinoma who have exhausted standard treatment options. The success of this trial could position C-13-60 as a novel therapeutic option in a competitive landscape dominated by existing CAR-T therapies and immune checkpoint inhibitors. Given the high unmet need in these indications, particularly in late-stage cancers, there is significant market potential if the therapy demonstrates favorable outcomes. The trial's recruitment status is currently active, with an estimated completion date in 2027, indicating a long-term investment horizon for stakeholders.

A Phase 1/2 Trial (CheckCell-2) in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

Intima Bioscience, Inc. is advancing a novel approach to treating metastatic non-small cell lung cancer (NSCLC) through the genetic engineering of tumor-infiltrating lymphocytes (TILs) using CRISPR/Cas9 technology to inhibit the CISH checkpoint. This strategy aims to enhance the efficacy of TIL therapy, which has shown promise in other cancers like melanoma. The market for NSCLC therapies is substantial, with increasing demand for innovative treatments that improve patient outcomes. However, the trial has been withdrawn due to recruitment challenges, which may hinder the asset's development timeline and market entry. Competitive analysis indicates that while several companies are exploring TIL therapies and checkpoint inhibitors, the specific targeting of CISH represents a unique proposition that could differentiate Intima's approach if successfully validated.

Safety of Oral Activated Charcoal and Its Effect on the Gut Microbiome In Patients With Lung Cancer Undergoing Transcervical Extended Mediastinal Lymphadenectomy (TEMLA)

The study, sponsored by the Masonic Cancer Center at the University of Minnesota, aimed to assess the safety and microbiome effects of oral activated charcoal in lung cancer patients undergoing a specific surgical procedure (TEMLA). However, the trial has been withdrawn due to logistical challenges and product availability. This withdrawal may indicate potential hurdles in the commercialization of OAC for this indication, as well as the need for further exploration of its clinical utility in solid tumors before considering hematologic malignancies. The market for supportive care in oncology is significant, but the competitive landscape includes established therapies and emerging agents targeting similar patient populations. Further diligence is required to assess the viability of OAC in this context and its potential integration into standard care protocols.

Phase I/II Study of Anti-MUC1 CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

PersonGen BioTherapeutics is advancing a novel CAR T cell therapy targeting MUC1+ advanced refractory solid tumors, including hepatocellular carcinoma, non-small cell lung cancer, pancreatic carcinoma, and triple-negative breast cancer. The market for CAR T therapies is expanding, particularly in oncology, with increasing demand for treatments addressing solid tumors. The competitive landscape includes established players like Novartis and Gilead, but PersonGen's focus on MUC1 may provide a unique positioning. The trial's recruitment status indicates ongoing interest and potential for future partnerships or acquisitions, particularly if early results demonstrate safety and efficacy.

Matched by conditions: Non-small Cell Lung Cancer